Home
Information
European Medicines Agency Orphan Drug Status
Summary of Product Characteristics (SPC)
Technology
Clinical Development
Publications & Scientific Papers
Review Articles
Clinical Publications
Pre-Clinical Publications
Tools & Forms
Patient Informed Concent
Contact
Preclinical Publications
Title
Date
Comparison of Cisplatin with Lipoplatin in Terms of Ototoxicity
2018
Lipoplatin CHUV Ris Hans-Beat manipulation of tumor blood vessels
2018
Safety and efficacy of quadrapeutics versus chemoradiation in head and neck carcinoma xenograft model
2015
Preclinical evaluation of a new liposomal formulation of cisplatin, lipoplatin, to treat cisplatin-resistant cervical cancer
2013
Optimization of the route of platinum drugs administration to optimize the concomitant treatment with radiotherapy for glioblastoma implanted in the Fischer rat brain
2013
Preparation, Biodistribution and Neurotoxicity of Liposomal Cisplatin following Convection Enhanced Delivery in Normal and F98 Glioma Bearing Rats
2012
Glioblastoma Treatment: Bypassing the Toxicity of Platinum Compounds by Using Liposomal Formulation and Increasing Treatment Efficiency With Concomitant Radiotherapy
2012
Cellular uptake and cytoplasm / DNA distribution of cisplatin and oxaliplatin and their liposomal formulation in human colorectal cancer cell HCT116
2011
In vivo comparative study of the cytotoxicity of a liposomal formulation of cisplatin (lipoplatinTM)
2011
Intrapleural administration of lipoplatin in an animal model
2010
Concomitant treatment of F98 glioma cells with new liposomal platinum compounds and ionizing radiation
2010
Distribution of Free and Liposomal Doxorubicin After Isolated Lung Perfusion in a Sarcoma Model
2008
Activity of lipoplatin in tumor and in normal cells in vitro
2008
Potential of the Akt inhibitor LY294005 to antagonize the efficacy of Cisplatin against HCT116 tumor cells in a DNA mismatch repair-dependent manner
2006
MLH1-deficient tumor cells are resistant to lipoplatin, but retain sensitivity to lipoxal
2005
Preclinical evaluation of a liposome-encapsulated formulation of cisplatin in clinically normal dogs
2004
Low Renal Toxicity of Lipoplatin Compared to Cisplatin in Animals
2004
Low toxicity and anticancer activity of a novel liposomal cisplatin (Lipoplatin) in mouse xenografts
2004
© 2018 Regulon Group - Lipoplatin is a licensed product of
Regulon Inc.